Oliver A. Sartor

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis et al. · European Urology · 2022 · 114 citations · Full text

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen, Fabio Turco, Ian D. Davis et al. · European Urology · 2024 · 87 citations · Full text

Interactions of cytokine gene polymorphisms in prostate cancer risk

Jovanny Zabaleta, Hui‐Yi Lin, Rafael A. Sierra et al. · Carcinogenesis · 2007 · 68 citations · Full text

ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mary‐Ellen Taplin, Arif Hussain, Satish Shah et al. · Journal of Clinical Oncology · 2019 · 16 citations

Phase 1B, Urology, Oncology +15